CSL’s $800 million vaccine manufacturing facility in Melbourne nears completion
MAY 21, 2023
CSL Seqirus has reached a major milestone in the construction of its new cutting-edge manufacturing facility for vaccine and antivenom manufacturing. The $800 million Tullamarine-based facility is now at its highest point of construction known as “topping out,” which is marked by the completion of roofing laying on the building. The manufacturing facility will have CSL Seqirus vaccine adjuvant technology (MFS59) to manufacture seasonal and pandemic cell-based influenza vaccines.
Let's personalize your content